Drug Trial News

RSS

PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.

15 Jun 2016

FDG-PET imaging tracks ability of atezolizumab to bolster immunity against NSCLC

Non-small cell lung cancers have a collective reputation for not responding very well to chemotherapy. Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are presenting a means of evaluating an immunotherapy that fights off NSCLC by strengthening a patient's own immune system.

14 Jun 2016

Clinical trial to test efficacy of new drug for chronic cough

The National Institute for Health Research has today announced its participation in a clinical trial to test a promising new treatment for chronic cough. If approved, this would be the first new cough drug in 50 years and offer hope to the millions of people living with chronic cough for whom few, if any, effective treatments exist.

14 Jun 2016

New vaccine found safe, effective against Toxic Shock Syndrome

Toxic Shock Syndrome (TSS) is a severe circulatory and organ failure caused by bacterial toxins, usually triggered by bacteria from the Staphylococcus group. Researchers from MedUni Vienna's Department of Clinical Pharmacology, in collaboration with the company Biomedizinische Forschungsgesellschaft mbH in Vienna, have now developed the world's first safe and effective vaccine against this disease and successfully tested it in a Phase I trial.

13 Jun 2016

Inotuzumab ozogamicin study reveals complete remission rates higher than standard therapy for ALL patients

In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.

13 Jun 2016

New drug ixekizumab helps clear severe psoriasis symptoms

About 80 percent of patients with moderate to severe psoriasis saw their disease completely or almost completely cleared with a new drug called ixekizumab, according to three large, long-term clinical trials led by Northwestern Medicine.

10 Jun 2016

Nivolumab drug benefits metastatic RCC patients who continued treatment beyond progression

In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed.

7 Jun 2016

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting.

7 Jun 2016

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

Targeted therapy rucaparib shows promise in treating pancreatic cancer patients with BRCA mutation

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study presented by Susan M. Domchek, MD, executive director of the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, at the American Society of Clinical Oncology Annual Meeting.

6 Jun 2016

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

The experimental "smart-bomb" drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer (SCLC), according to results from a first-in-human clinical trial to be presented today by a Memorial Sloan Kettering Cancer Center researcher at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.

6 Jun 2016

New technique could help reduce chances of drug failure during later stages of clinical trials

An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline.

2 Jun 2016

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

An immune-based therapy developed at Roswell Park Cancer Institute is moving forward with its third clinical trial. The early-stage clinical trial will assess whether SurVaxM — a cancer vaccine developed at Roswell Park — is a safe and effective treatment option for patients with multiple myeloma, a rare type of blood cancer.

1 Jun 2016

$ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients$

ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn.

26 May 2016

First clinical trial to study use of Chinese Herbal Medicines in treating RUTIs

Researchers at the University of Southampton are to study the use of Chinese Herbal Medicines in treating recurrent urinary tract infections (RUTIs), in the first clinical trial of its kind in the UK.

25 May 2016

Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment from an anonymous contributor who originally invested $4 million to help get the compound this far in the drug-approval pipeline.

25 May 2016

Aliskiren fails to show benefit for heart failure patients with diabetes

A subgroup analysis in heart failure patients with diabetes from the ATMOSPHERE trial has failed to show benefit and signals the end of the road for aliskiren in heart failure.

24 May 2016

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.

23 May 2016

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.

23 May 2016

Drug Trial News

PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

FDG-PET imaging tracks ability of atezolizumab to bolster immunity against NSCLC

Clinical trial to test efficacy of new drug for chronic cough

New vaccine found safe, effective against Toxic Shock Syndrome

Inotuzumab ozogamicin study reveals complete remission rates higher than standard therapy for ALL patients

New drug ixekizumab helps clear severe psoriasis symptoms

Nivolumab drug benefits metastatic RCC patients who continued treatment beyond progression

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

Targeted therapy rucaparib shows promise in treating pancreatic cancer patients with BRCA mutation

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

Nivolumab drug shows better response rate in metastatic bladder cancer patients

New technique could help reduce chances of drug failure during later stages of clinical trials

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

First clinical trial to study use of Chinese Herbal Medicines in treating RUTIs

Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Aliskiren fails to show benefit for heart failure patients with diabetes

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News